1. Home
  2. ACAD vs AGO Comparison

ACAD vs AGO Comparison

Compare ACAD & AGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACAD
  • AGO
  • Stock Information
  • Founded
  • ACAD 1993
  • AGO 2003
  • Country
  • ACAD United States
  • AGO Bermuda
  • Employees
  • ACAD N/A
  • AGO N/A
  • Industry
  • ACAD Biotechnology: Pharmaceutical Preparations
  • AGO Property-Casualty Insurers
  • Sector
  • ACAD Health Care
  • AGO Finance
  • Exchange
  • ACAD Nasdaq
  • AGO Nasdaq
  • Market Cap
  • ACAD 4.0B
  • AGO 4.1B
  • IPO Year
  • ACAD 2004
  • AGO 2004
  • Fundamental
  • Price
  • ACAD $25.74
  • AGO $82.54
  • Analyst Decision
  • ACAD Buy
  • AGO Buy
  • Analyst Count
  • ACAD 20
  • AGO 2
  • Target Price
  • ACAD $28.63
  • AGO $98.50
  • AVG Volume (30 Days)
  • ACAD 2.0M
  • AGO 339.6K
  • Earning Date
  • ACAD 08-06-2025
  • AGO 08-07-2025
  • Dividend Yield
  • ACAD N/A
  • AGO 1.66%
  • EPS Growth
  • ACAD 615.00
  • AGO N/A
  • EPS
  • ACAD 1.33
  • AGO 9.06
  • Revenue
  • ACAD $1,018,885,000.00
  • AGO $891,000,000.00
  • Revenue This Year
  • ACAD $13.28
  • AGO N/A
  • Revenue Next Year
  • ACAD $10.88
  • AGO N/A
  • P/E Ratio
  • ACAD $18.70
  • AGO $9.07
  • Revenue Growth
  • ACAD 14.41
  • AGO 3.01
  • 52 Week Low
  • ACAD $13.40
  • AGO $74.09
  • 52 Week High
  • ACAD $25.88
  • AGO $96.50
  • Technical
  • Relative Strength Index (RSI)
  • ACAD 66.52
  • AGO 48.40
  • Support Level
  • ACAD $24.47
  • AGO $80.14
  • Resistance Level
  • ACAD $25.88
  • AGO $81.85
  • Average True Range (ATR)
  • ACAD 0.71
  • AGO 1.46
  • MACD
  • ACAD 0.00
  • AGO -0.10
  • Stochastic Oscillator
  • ACAD 94.62
  • AGO 37.37

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

About AGO Assured Guaranty Ltd.

Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.

Share on Social Networks: